Shared-link access · Not indexed
Tesamorelin Dosing Calculator
A step-by-step calculator for reconstitution volumes, syringe draw, and protocol reference. Educational use only — all dosing decisions require a licensed medical provider.
Read full Tesamorelin profile →1
Peptide2
Vial Setup3
Regimen4
CardTesamorelin
Also known as: Tesamorelin acetate, TH9507, Egrifta, Egrifta SV
Clinical / FDA-approved — Protocol evidence level
FDA-approved (Egrifta) GHRH analog for the reduction of excess abdominal fat in HIV-associated lipodystrophy. The original Egrifta is 2 mg SC once daily; the EGRIFTA SV reformulation is 1.4 mg SC once daily. Off-label use for general body composition or anti-aging is not proven and not approved.
Last reviewed: 2026-06-12
Contraindications — Do not use if:
- •Pregnancy (Egrifta is contraindicated — discontinue if pregnancy occurs)
- •Disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation/trauma)
- •Active malignancy
- •Hypersensitivity to tesamorelin or mannitol